Home > Boards > US Listed > Biotechs > PharmaCyte Biotech Inc. (PMCB)


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
longboarder7892 Member Profile
Followed By 20
Posts 2,221
Boards Moderated 4
Alias Born 12/06/17
160x600 placeholder
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference Business Wire - 1/6/2022 9:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/4/2022 10:44:02 AM
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells Business Wire - 1/4/2022 9:00:00 AM
PharmaCyte completes stability study as part of process to get clinical hold lifted Seeking Alpha - 12/28/2021 9:41:47 AM
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study Business Wire - 12/28/2021 9:00:00 AM
PharmaCyte Biotech reports FQ2 results Seeking Alpha - 12/15/2021 9:08:54 AM
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights Business Wire - 12/15/2021 9:00:00 AM
Analysts Offer Insights on Consumer Goods Companies: Aspen Group (ASPU) and PharmaCyte Biotech (PMCB) TipRanks - 12/15/2021 6:16:39 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 12/14/2021 5:17:29 PM
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay Business Wire - 12/8/2021 10:16:00 AM
H.C. Wainwright Keeps a Hold Rating on PharmaCyte Biotech (PMCB) TipRanks - 11/30/2021 12:05:16 PM
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study Business Wire - 11/30/2021 1:05:00 AM
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation Business Wire - 11/12/2021 9:00:00 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 11/8/2021 6:01:27 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 11/4/2021 7:39:35 AM
PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA Business Wire - 9/27/2021 9:00:00 AM
PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests Business Wire - 9/21/2021 9:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 9/14/2021 8:02:08 AM
PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference Business Wire - 9/8/2021 9:00:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/3/2021 7:20:53 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 9/1/2021 6:04:10 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/31/2021 6:25:24 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/31/2021 6:24:54 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/31/2021 6:24:23 PM
PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study Business Wire - 8/31/2021 9:20:00 AM
longboarder7892   Tuesday, 09/07/21 01:15:53 PM
Re: None
Post # of 144217 

Anthony Cataldo

PharmaCyte Biotech: Buy The 'Dump'
"I recommend that you nibble a few shares of PharmaCyte Biotech

"If the investment community can be convinced that the PharmaCyte drug pipeline shows promise, it is not inconceivable that a large pharmaceutical may exhibit some interest - preferably financial interest or partnering interest. This could be very rewarding to shareholders choosing to enter at current PPS levels. I am willing to accept the risk/reward, at least for a few quarters and until I can re-evaluate the firm's cash burn and fundamentals."

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences